Update Series (2019) Lesson 19: Integrating Surgical and Systemic Therapies in the Management of Metastatic and High Risk Non-Metastatic Renal Cell Carcinoma
Now in its 38th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed in consultation with and edited by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
At the conclusion of this continuing medical education activity, the participant will be able to describe the systemic therapies available for advanced renal cell carcinoma and their mechanisms of action, the merits of neoadjuvant and adjuvant systemic therapies for high risk non-metastatic renal cell carcinoma, and the role of cytoreductive nephrectomy for newly diagnosed metastatic renal cell carcinoma in the modern era.
Bimal Bhindi, MD, CM, MSc, FRCSC
Disclosures: Nothing to disclose
Department of Surgery, Section of Urology
Southern Alberta Institute of Urology
Stephen A. Boorjian, MD, FACS
Disclosures: Ferring: Consultant
Department of Urology
Brian A. Costello, MD, MS
Disclosures: Nothing to disclose
Department of Oncology
This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Individual authors’ disclosures are located with their articles in each issue of The Update Series.
Update Series Advisory Group
|Benjamin Newell Breyer, MD, FACS||World Journal Urology||Health Publishing|
|Sexual Medicine Open Access||Health Publishing|
|Arthur Louis Burnett II, MD, MBA||Endo Pharmaceuticals||Scientific Study or Trial|
|PFIZER||Scientific Study or Trial|
|National Institutes of Health||Scientific Study or Trial|
|Auxilium Inc||Scientific Study or Trial|
|American Medical Systems/Boston Scientific||Scientific Study or Trial|
|Coloplast||Scientific Study or Trial|
|Reflexonic LLC||Scientific Study or Trial|
|UMarvl||Consultant or Advisor, Scientific Study or Trial|
|Novartis Pharmaceuticals||Consultant or Advisor, Scientific Study or Trial|
|Futura Medical||Consultant or Advisor, Scientific Study or Trial|
|Acorda Therapeutics||Scientific Study or Trial|
|Andrology (journal)||Health Publishing|
|International Urology and Nephrology (journal)||Health Publishing|
|Astellas||Consultant or Advisor, Scientific Study or Trial|
|Urology Times Editorial Council||Health Publishing|
|Lilly LLC||Consultant or Advisor, Scientific Study or Trial|
|Shelby Englert||Nothing to disclose|
|E. Ann Gormley, MD||ACGME||Leadership Position|
|AUA Updates||Leadership Position|
|Cheryl Taylore Lee, MD||merck||Consultant or Advisor|
|David Christopher Miller, MD, MPH||Blue Cross Blue Shield of Michigan||Other|
|National Cancer Institute||Scientific Study or Trial|
|Curtis Nickel, MD||Farr Laboratories||Consultant or Advisor|
|Aquinox||Scientific Study or Trial|
|NIH||Scientific Study or Trial|
|Canadian Institute of Health Research||Scientific Study or Trial|
|Alvio Therapeutics||Consultant or Advisor|
|Seikagaku Corporation||Consultant or Advisor|
|RedLeaf Medical||Scientific Study or Trial|
|TEVA||Consultant or Advisor|
|Craig Stuart Niederberger, MD||AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE||Leadership Position, Meeting Participant or Lecturer|
|NexHand||Leadership Position, Investment Interest, Owner, Product Development|
|Ferring Pharmaceuticals||Scientific Study or Trial|
|Victor William Nitti, MD||Astellas||Health Publishing, Scientific Study or Trial|
|Allergan||Health Publishing, Scientific Study or Trial|
|Serenity Pharmeuticals||Investment Interest|
|Cook Myosite||Scientific Study or Trial|
|Medtronic||Scientific Study or Trial|
|Mrs. Deborah F. Polly||Nothing to disclose|
|Eila Curlee Skinner, MD||Genentech||Scientific Study or Trial|
|Stacy T. Tanaka, MD||AUA Update Series||Health Publishing|
|Journal of Urology||Health Publishing|
|Centers for Disease Control and Prevention (CDC)||Scientific Study or Trial|
|American Board of Urology||Other|
|American Academy of Pediatrics, Section on Urology||Leadership Position|
|J. Christian Winters, MD||StimGuard||Consultant or Advisor|
|J. Stuart Wolf Jr., MD., FACS||Urology Times||Health Publishing|
|University of Texas Department of Surgery & Peri-operative Care||Leadership Position|
|American Board of Urology||Leadership Position|
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.
Peer Review: Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Advisory Board.
Released date: June 2019
Expiration date: June 2022
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation